The Tumor Microenvironment and Its Role in Cancer Metastasis: A Survey

www.surveyx.cn

Abstract

The tumor microenvironment (TME), encompassing non-cancerous cells, signaling molecules, and the extracellular matrix, plays a critical role in cancer progression and metastasis. This survey paper provides a comprehensive analysis of the TME's influence on cancer dynamics, emphasizing its role in processes such as epithelial-to-mesenchymal transition (EMT) and organ-specific metastasis. The study highlights the potential of biomarkers, particularly imaging and genomic biomarkers, in enhancing predictive modeling of treatment responses. It also explores the challenges and innovations in modeling cancer metastasis, emphasizing the integration of hybrid and nonparametric approaches to improve prognostic accuracy. The paper delves into the complexity of molecular pathways and their contributions to metabolic reprogramming, underscoring the importance of understanding tumor-immune interactions. By integrating multimodal and multiscale data, the research aims to provide a nuanced understanding of cancer dynamics, informing the development of targeted therapies. Future directions include elucidating molecular pathways involved in metastasis, exploring the role of non-genetic heterogeneity, and advancing predictive modeling techniques. The paper concludes by emphasizing the significance of targeting the TME and metabolic vulnerabilities in developing effective therapeutic strategies, ultimately improving patient outcomes and advancing oncology research.

1 Introduction

1.1 Significance of the Tumor Microenvironment (TME)

The tumor microenvironment (TME) is integral to cancer biology, significantly influencing cancer progression and metastasis. Rather than a mere backdrop, the TME actively participates in tumorigenesis by modulating gene regulatory networks crucial for cancer development and therapeutic responses [1]. Comprising non-cancerous cells, signaling molecules, and the extracellular matrix, the TME collectively enhances tumor growth and metastatic potential [2].

A key process orchestrated by the TME is the epithelial-to-mesenchymal transition (EMT), which endows cancer cells with the motility and invasiveness required for metastasis. This transition is tightly regulated by the TME, underscoring its role in the metastatic decision-making of cancer cells [2]. Additionally, the TME facilitates organ-specific metastasis, presenting unique challenges for metastatic tumor cells, particularly in environments like the brain, which differ markedly from other sites.

Exosomes within the TME are vital mediators of intercellular communication, particularly under hypoxic conditions, and represent promising clinical targets for cancer therapy. The TME's role in tumor-induced angiogenesis is critical for tumor growth and metastasis, facilitating interactions between cancer cells and various host cells, including endothelial and immune cells. Understanding these complex interactions is essential for developing effective therapeutic interventions; targeting



Figure 1: chapter structure

specific TME components—such as tumor-associated macrophages, cancer-associated fibroblasts, and the extracellular matrix—could enhance treatment efficacy and inhibit cancer progression [3, 4].

The complexity and essential role of the TME in cancer underscore its significance in research. A thorough understanding of the TME is vital for developing prognostic tools and therapeutic strategies, as it profoundly influences tumor growth, metastatic spread, and treatment responses. By managing the intricate interactions within the TME—encompassing immune cells, stromal components, and the extracellular matrix—researchers can improve treatment efficacy and clinical outcomes for cancer patients, thereby advancing oncology [5, 6, 3, 4].

1.2 Scope of the Paper

This paper provides a comprehensive examination of the TME and its pivotal role in cancer progression, focusing on the intricate interactions between cancer cells and TME constituents, including immune cells, fibroblasts, and the extracellular matrix. It discusses how these interactions facilitate

tumor initiation, invasion, and metastasis, while exploring therapeutic strategies targeting specific TME components to enhance treatment efficacy and overcome resistance [7, 8, 3, 9, 10]. The significance of both epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) in metastasis is highlighted, as these processes are intricately regulated by gene networks within the TME. Furthermore, the paper investigates homeostatic pressure as a novel measure of metastatic potential, offering insights into tumor growth dynamics and metastatic behavior.

The exploration of biomarkers in cancer research is another focal point, emphasizing the discovery and application of imaging biomarkers to enhance predictive modeling of treatment responses, particularly through dynamic contrast-enhanced MRI (DCE-MRI) [11]. Limitations of previous methodologies are addressed, including innovative approaches like the Bayesian Meta-Analysis for Biomarker Subgroups (BMABS) for evaluating treatment effects in biomarker-positive patients [1].

In the context of organ-specific transfer during metastasis, the paper examines the unique microenvironmental conditions of brain metastases, considering cellular interactions and therapeutic challenges posed by cancers such as lung, breast, and melanoma. An in-depth analysis of the functional heterogeneity of cancer-derived exosomes in hypoxic TMEs emphasizes their role in enhancing intercellular communication and their potential as therapeutic targets. Hypoxia's influence on exosome biogenesis and size variation may facilitate cancer cell adaptation, metastasis, and resistance to therapies. Understanding the mechanisms through which exosomes mediate communication underscores the importance of targeting these pathways for effective cancer treatments [7, 3, 12].

Predictive modeling is emphasized as a cornerstone of this research, focusing on integrating historical and current data to improve prognostic predictions and inform therapeutic strategies. This includes applying systems biology tools to investigate regulatory mechanisms in cancer metastasis and utilizing advanced modeling techniques to predict neoadjuvant chemotherapy (NAC) responses in triple-negative breast cancer (TNBC) patients [13]. Through these analyses, the paper aims to provide a comprehensive understanding of cancer progression and inform the development of effective therapeutic strategies.

1.3 Structure of the Survey

The survey is structured to provide a comprehensive understanding of the TME and its role in cancer metastasis. It begins with an introduction to the TME's significance in cancer research, setting the stage for a detailed exploration of its components and functions. Existing research is organized into categories focusing on molecular mechanisms, TME influences, and therapeutic approaches [14], further refined by considering the roles of malignant versus non-malignant cells during tumor initiation, progression, and metastasis [15].

The survey proceeds to a background section that defines key concepts, including biomarkers, organ-specific transfer, molecular pathways, and predictive modeling. This foundational knowledge supports a detailed examination of TME components—such as the extracellular matrix (ECM), stromal cells, and immune cells—and their roles in promoting or inhibiting metastasis. Recent technological advances in analyzing TME interactions and their therapeutic implications are also discussed.

Subsequently, the survey delves into the role of biomarkers in cancer research, emphasizing their application in diagnosis, prognosis, and treatment response prediction. The discussion extends to organ-specific transfer and metastasis, exploring mechanisms and factors influencing this process. A key innovation is the cross-scale analysis method that integrates molecular signaling with cellular dynamics, identifying critical pathway components influencing tumor expansion [16].

The survey further analyzes molecular pathways involved in cancer progression, focusing on cellular interactions that lead to behavioral changes and tumor development. The final sections explore predictive modeling techniques and algorithms used to forecast disease progression and treatment responses, highlighting emerging trends and future directions in cancer research. Through this structured approach, the survey aims to provide a holistic view of cancer progression, informing the development of effective therapeutic strategies.The following sections are organized as shown in Figure 1.

2 Background and Definitions

2.1 Background and Definitions

A comprehensive understanding of cancer progression and metastasis necessitates examining foundational concepts such as the tumor microenvironment (TME), biomarkers, organ-specific metastasis, molecular pathways, and predictive modeling. The TME, comprising non-cancerous cells, signaling molecules, and the extracellular matrix (ECM), plays a pivotal role in tumor development and creates an immunosuppressive environment that reduces the efficacy of cancer therapies. In pancreatic cancer, desmoplasia and immune evasion are prominent factors in tumor progression [17]. Dysregulated molecules like CD44 within the TME further impact cancer progression and therapeutic resistance [18].

Biomarkers, essential for diagnosing, prognosticating, and predicting cancer treatment responses, face challenges due to the complex interplay of disease indicators and unobserved biomarker heterogeneity, complicating survival outcome modeling [1]. The advancement of cancer understanding and treatment, particularly in personalized medicine, depends on the integration of heterogeneous data modalities [19].

Organ-specific metastasis involves cancer cells spreading from the primary tumor to distant organs, leading to secondary tumor formation [20]. This process is intricately linked to the TME and involves metastasis-initiating cells (MICs) capable of surviving the metastatic cascade and establishing new tumor growth [21]. The brain microenvironment poses unique challenges for metastatic cells, such as metabolic constraints and the blood-brain barrier (BBB), complicating successful colonization [22].

Molecular pathways, comprising complex interactions among cellular molecules, significantly influence tumor progression. The role of RNMT in tumor development and immune regulation is noteworthy across various cancers [23]. Understanding transcriptional heterogeneity among cancer cells is vital for comprehending tumor progression, metastasis, and treatment failure, highlighting interactions with the TME [24]. A significant challenge is quantitatively linking molecular signaling to cellular behavior, especially in non-small cell lung cancer (NSCLC), which hinders insights into cancer dynamics [16].

Predictive modeling utilizes statistical techniques and algorithms to forecast disease progression and treatment responses, leveraging historical and current data. This approach is crucial for developing effective therapeutic strategies and enhancing prognostic predictions in cancer research [25]. Challenges include integrating diverse data types, managing incomplete modalities, and ensuring robust performance across clinical tasks [19]. By synthesizing these concepts, researchers aim to unravel the complexities of cancer metastasis, the leading cause of cancer-related mortality [26]. Despite its critical role in cancer progression, the metastatic process remains poorly understood, necessitating further investigation [27].

In recent years, the understanding of the Tumor Microenvironment (TME) has evolved significantly, revealing its critical role in cancer progression. This understanding is enhanced by the insights provided by recent technological advancements in analysis, which allow for a more nuanced exploration of the TME's components and their interactions. As illustrated in Figure 2, the hierarchical structure of the TME is depicted, showcasing its key cellular components and the extracellular matrix. This figure highlights the complex signaling pathways and dynamic interactions that occur within the microenvironment, which are pivotal in influencing cancer progression. Furthermore, the advancements in methodology not only facilitate a deeper analysis of these interactions but also pave the way for potential therapeutic strategies aimed at improving treatment outcomes for cancer patients. Thus, the integration of these insights underscores the significance of the TME in both cancer biology and therapeutic development.

3 The Tumor Microenvironment (TME)

3.1 Components of the TME

The tumor microenvironment (TME) comprises non-cancerous cells, signaling molecules, and the extracellular matrix (ECM), significantly impacting cancer progression and metastasis. Key cells, including cancer-associated fibroblasts, tumor-associated macrophages, and neutrophils, influence



Figure 2: This figure illustrates the hierarchical structure of the Tumor Microenvironment (TME), highlighting its components, extracellular matrix interactions, microenvironmental dynamics, technological advances in analysis, and therapeutic implications. The TME comprises key cells and the extracellular matrix, influencing cancer progression through complex signaling and dynamic interactions. Technological and methodological advancements provide insights into TME analysis, offering potential therapeutic strategies for improved cancer treatment outcomes.

tumor biology and therapeutic outcomes, while regulatory T cells contribute to an immunosuppressive environment that hinders effective cancer therapy [12]. The ECM provides structural support and biochemical signals crucial for cellular interactions and tumor dynamics [28]. It is involved in processes like cell motility, invasion, and colonization, with matrix metalloproteinases facilitating ECM remodeling, which is vital for cancer diagnostics and monitoring [29]. Hypoxia, nutrient deprivation, and inflammation within the TME promote genomic instability and cancer progression, fostering aggressive phenotypes [12].

Exosomes facilitate intercellular communication under hypoxic conditions, with stages of biogenesis, cargo sorting, and uptake playing roles in tumor growth and metastasis [12]. The formation of motile cell clusters, driven by alignment interactions, illustrates the complexity of collective cell migration essential to metastasis [28]. Recent modeling advancements, including continuum, agent-based, mechanical, and hybrid models, provide diverse perspectives on ECM interactions, elucidating the TME's multifaceted nature [29].

As depicted in Figure 3, this figure illustrates the key components of the tumor microenvironment, highlighting the roles of non-cancerous cells, the extracellular matrix, and the effects of hypoxia and inflammation. Each component plays a crucial role in cancer progression and therapeutic resistance, as detailed in the referenced studies. Understanding these interactions is crucial for developing effective cancer therapies by enhancing comprehension of mechanisms driving cancer progression and treatment resistance.

3.2 Extracellular Matrix and Signaling Molecules

The ECM is a fundamental TME component, influencing cancer progression through structural and biochemical properties. It modulates cell behavior and communication between cancer cells and their environment. Alterations in the ECM, particularly through matrikines and matricryptins, affect cancer cell proliferation, migration, and invasion [9]. Mechanical properties like stiffness and elasticity regulate cancer cell morphodynamics, impacting metastatic potential [30]. The interplay between

AI-generated, for reference only.



Figure 3: This figure illustrates the key components of the tumor microenvironment, highlighting the roles of non-cancerous cells, the extracellular matrix, and the effects of hypoxia and inflammation. Each component plays a crucial role in cancer progression and therapeutic resistance, as detailed in the referenced studies.

ECM mechanics and the actomyosin cytoskeleton influences cell shape and movement dynamics, affecting processes like gap formation in endothelial barriers [31].

Signaling molecules, including cytokines, growth factors, and chemokines, modulate interactions between tumor cells and the ECM, facilitating invasion and promoting a supportive microenvironment for metastasis. These signals alter ECM composition and enhance cross-talk between cancer and stromal cells, impacting therapeutic responses and outcomes [3, 9, 10]. These interactions underscore the TME's complexity and its critical role in cancer progression, highlighting the need for therapeutic strategies targeting the TME to disrupt its supportive niche.

3.3 Microenvironmental Dynamics and Cancer Cell Behavior

The TME's dynamic nature profoundly influences cancer cell behavior and progression. The immunosuppressive environment inhibits immune cell activity, facilitating tumor growth [8]. Epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) underpin cancer cell plasticity, enabling transitions essential for metastasis [32]. Factors like homeostatic pressure and spatial interactions within the TME influence these dynamics, dictating tumor growth and metastatic potential. Mathematical models treat cancer cell phenotypes as continuous variables, allowing nuanced understanding of transitions between cellular states [33].

Spatial-temporal dynamics of pathways, such as those involving RhoA, vary between two-dimensional and three-dimensional environments, with cells showing more pronounced behavior in 2D [34]. Network motifs within cellular decision-making networks generate hybrid states, complicating EMT and MET processes [35]. Cancer development can be viewed as a two-phase model: initial plasticity for adaptation within molecular networks, followed by a rigidity phase influencing treatment outcomes [36]. This model illustrates the chaotic nature of tumor growth, shaped by initial conditions within the TME [37].

3.4 Technological Advances in TME Analysis

Technological advancements have enhanced TME analysis, providing insights into its complex dynamics. Novel imaging techniques, such as optical and magnetic resonance imaging, have improved spatial and temporal resolution, enabling precise characterization of tumor heterogeneity and interactions [38]. The PathoTME framework employs genomics-guided Siamese representation learning for pan-cancer TME subtype prediction [39], integrating genomic data with imaging to enhance predictive accuracy of cancer outcomes.

In predictive modeling, the energy landscape method combines mathematical modeling with experiments to quantify transition paths in cancer-associated conditions, revealing mechanisms of progression [40]. Deep learning in digital pathology highlights predictive capabilities through tissue scale analysis [41]. Multi-scale models incorporating ECM microstructure and mechanics have been developed to analyze cancer invasion [42], providing insights into mechanical aspects of cell movement.

Innovations in 3D culture systems, such as optical ratiometric pH sensors, offer real-time monitoring of pH fluctuations in the TME, providing a physiologically relevant context for studying tumor dynamics [43]. The IS3D-SMB method facilitates real-time biomarker dynamics analysis in 3D cell culture assays [44]. The DIGME strategy enables precise control over tumor organoid shape and ECM heterogeneity, facilitating cancer invasion studies [45]. Machine learning-assisted techniques, integrating FRET biosensors, offer insights into spatial-temporal dynamics of cancer cell behavior [34]. These advancements highlight the potential of integrating computational, imaging, and experimental techniques in TME analysis, paving the way for personalized cancer therapies.

3.5 Therapeutic Implications and TME Management

The TME is increasingly recognized as a pivotal target for therapeutic interventions due to its role in cancer progression and metastasis. Addressing the TME's impact on cancer cell behavior and therapeutic resistance requires a comprehensive strategy that integrates cellular and acellular components and their interactions. This is crucial for developing therapies that counteract the TME's effects while exploiting cancer cells' vulnerabilities [46, 47, 6, 3, 48]. Recent advancements emphasize modulating immune responses and stromal interactions to enhance treatment outcomes, with potential to disrupt the supportive niche facilitating tumor growth and therapy resistance.

Nanotechnology has emerged as a promising avenue for targeted therapies, particularly in metastatic cancer, enabling direct delivery of agents to the TME, improving drug efficacy. Ratiometric fluorescence for monitoring TME parameters enhances therapeutic response assessment [28]. Mathematical modeling has identified critical parameters for clinical decision-making, providing insights into effective treatment strategies by capturing cancer growth and vascularization dynamics [29]. Models highlight the importance of ECM stiffness, fiber orientation, and signaling in regulating cell behavior, predicting complex biological behaviors [2].

Machine learning approaches, like NaroNet, utilize embeddings to identify and annotate TMEs, facilitating patient classification. Explainable AI models analyze TME features and survival rates, providing insights into immune cells' contributions to prognosis [11]. The DIGME strategy allows control over tumor organoid shape and microenvironment, aiding in investigating cancer cell-ECM interactions. Targeting stromal components to enhance CAR T cell therapy efficacy in solid tumors is emerging as a strategy to address immunosuppressive barriers. By focusing on stromal interactions and selecting appropriate CAR targets, researchers aim to improve CAR T cell therapy outcomes [7, 3, 49, 4].

Integrating systems biology tools to analyze the CRKL regulatory network provides therapeutic implications for targeting the ERK1/2 pathway in breast cancer [50]. Understanding molecular players and pathways in metastasis lays the groundwork for identifying therapeutic targets, informing the development of more effective therapies.

4 Biomarkers in Cancer Research

The exploration of biomarkers in cancer research is crucial at the intersection of molecular biology, computational techniques, and clinical application. This section elucidates the multifaceted roles of biomarkers in understanding cancer mechanisms and enhancing patient management. We focus on computational and imaging biomarkers, which have become essential for non-invasive tumor assessment and treatment optimization. By integrating advanced imaging modalities with computational methodologies, researchers unveil insights that contribute to personalized cancer therapy, fostering a nuanced approach to oncology.

4.1 Computational and Imaging Biomarkers

The integration of computational and imaging techniques has revolutionized biomarker identification and application in cancer research, paving the way for precision medicine and improved clinical decision-making. Imaging biomarkers (IBs) from modalities like MRI and PET facilitate non-invasive tumor assessments, offering critical insights into cancer progression and treatment responses [51]. These biomarkers enhance visualization and quantification of tumor dynamics, aiding patient stratification and therapeutic customization.

Computational methodologies further advance the field by integrating complex datasets to clarify relationships between biomarkers and clinical outcomes. Neural network algorithms for image segmentation and analysis enhance tracking of dynamic cellular processes, such as RhoA dynamics in the tumor microenvironment [34]. The GERBIL framework utilizes a multi-agent system for data collection, embedding biomarker knowledge into a continuous space, thereby enhancing biomarker discovery and application [52].

Innovative methods like the BOSS algorithm optimize biomarker selection and cutoff values, improving predictive accuracy of biomarker-based models [53]. Additionally, leave-one-study-out (LOSO) cross-validation has been proposed as a superior method for estimating future biomarker performance compared to traditional K-fold cross-validation, ensuring robust findings [54].

The fusion of histological and genomic data through multimodal layers, exemplified by attention-based multiple instance learning networks, highlights the importance of diverse data types in comprehensive cancer risk assessment [55]. The PMBT model employs bioinformatics and machine learning to classify patients based on immune and stromal activity, showcasing the potential of computational tools in biomarker research [56].

In situ detection methods, such as quantifying fluorescence intensity from ELISA beads in 3D cultures, exemplify the convergence of computational and imaging biomarkers, enabling near real-time monitoring of biomarker dynamics within the tumor microenvironment [44]. These advancements underscore the transformative potential of integrating computational and imaging techniques in biomarker discovery and application, ultimately contributing to improved patient outcomes and advancements in cancer diagnostics and therapeutics.

4.2 Genomic and Molecular Biomarkers

Genomic and molecular biomarkers are pivotal in cancer research, offering insights into genetic and molecular alterations driving tumorigenesis and informing personalized treatment strategies. These biomarkers identify specific genetic mutations and expression profiles associated with cancer progression, facilitating the development of targeted therapies. For example, CXCR6 has been identified as a biomarker for aggressive melanoma cancer stem cells (CSCs), highlighting its role in asymmetric self-renewal and potential as a therapeutic target. However, the lack of a perfect biomarker for CSCs complicates accurate tumor control probability (TCP) assessment and treatment efficacy evaluation [1].

Integrating genomic data with pathological imaging enhances predictive accuracy in clinical outcome assessments through multi-task learning models, which estimate treatment effects by analyzing imaging data. This approach identifies predictive imaging biomarkers that inform personalized treatment strategies, leveraging pre-treatment images to uncover causal relationships and integrating diverse modalities such as RNA-seq and copy number variations. Advanced techniques like the Multimodal Cross-Task Interaction framework improve feature extraction from imaging and genomic data, contributing to better prognostic predictions and treatment response evaluations [19, 57, 58, 59, 55]. This underscores the importance of merging diverse data types for holistic cancer risk evaluation. Moreover, multivariate regression models using latent overlapping cluster indicators elucidate complex relationships between genomic features and drug responses, emphasizing the intricacies of precision medicine.

Network-guided biomarker discovery approaches effectively address the challenge of identifying relevant biomarkers from high-dimensional genomic datasets, where features often outnumber samples. By leveraging biological networks, these methods assume that interconnected genetic features are likely to collaboratively influence the phenotype of interest, enhancing feature selection processes. Innovative algorithms like P-Net utilize a sample network rather than biomarkers to predict clinical outcomes, offering new perspectives in precision medicine [60, 61]. Identifying gene interactions that indicate treatment response, particularly in breast cancer, exemplifies the pivotal role of genomic and molecular biomarkers in elucidating cancer progression. Topological data analysis also plays a crucial role in identifying significant gene interactions and biomarker features correlating with survival probability, offering novel insights into biomarker discovery.

Recent advancements have led to the emergence of topological biomarkers, such as TopoTxR, derived from dynamic contrast-enhanced MRI (DCE-MRI) data. These biomarkers capture complex breast tissue structures, predicting treatment responses in breast cancer patients. By focusing on biologically

relevant tissue structures, TopoTxR effectively distinguishes between patients who respond favorably to neoadjuvant chemotherapy and those who do not, enhancing personalized treatment strategies. This approach complements methodologies like Weighted Gene Topological Data Analysis (WGTDA), which employs topological principles to uncover intricate gene interactions and improve prognostic accuracy in cancer biomarker discovery. Together, these developments highlight the potential of integrating advanced imaging and genomic analyses to refine treatment plans and enhance patient outcomes in breast cancer care [62, 11, 59, 63, 64]. Furthermore, frameworks like GERBIL efficiently compress biomarker knowledge into an embedding space, enhancing the search for optimal biomarker subsets and outperforming existing methodologies.

4.3 Biomarkers in Personalized Medicine

The application of biomarkers in personalized medicine has transformed cancer treatment by tailoring therapeutic strategies to individual patients based on genomic and molecular insights. This approach enhances treatment efficacy and minimizes adverse effects by considering each patient's unique tumor characteristics. Integrative platforms, such as those discussed by Ding et al., facilitate patient stratification using genomic data, optimizing treatment plans [65]. Such stratification is essential for identifying patients most likely to benefit from specific therapies.

Recent advancements in computational methods, including explainable artificial intelligence (XAI) models, further enhance personalized treatment plans. Chakraborty et al. demonstrate how XAI models analyze immune cell fractions within the tumor microenvironment (TME) to tailor treatment strategies for breast cancer patients, providing insights into the immune landscape and its therapeutic impact [66]. Similarly, integrating spatial histological interactions within the TME, as highlighted by Li et al., improves prediction accuracy for neoadjuvant chemotherapy (NAC) responses, contributing to personalized medicine approaches [13].

Selecting optimal biomarker combinations is crucial for effective treatment selection in personalized medicine. Dasgupta et al. address previous methods' limitations by proposing strategies that balance precision with economic considerations, ensuring biomarker measurement costs are accounted for [67]. The BOSS algorithm refines this process by efficiently identifying optimal cutoff values for biomarkers, enhancing predictive accuracy of biomarker-based models [53].

In clinical trials, integrating predictive biomarkers is pivotal for enhancing trial efficiency and outcomes. Lu et al. discuss applying these biomarkers to identify patient subsets likely to respond positively to treatments, improving trial design [68]. Systematic hypothesis testing approaches, as proposed by Gao et al., allow for identifying patient subgroups through generalized linear models, addressing patient heterogeneity in disease [69].

As illustrated in Figure 4, the hierarchical structure of biomarkers in personalized medicine highlights key areas such as patient stratification, biomarker selection, and clinical trials. Each category encompasses significant advancements and methodologies that contribute to the field, emphasizing the utilization of genomic data, feature selection methods, and the integration of predictive biomarkers in trial designs.

4.4 Emerging Biomarkers and Future Directions

Biomarker research in oncology is advancing significantly, driven by integrating computational models with traditional methodologies, enhancing cancer diagnostics and treatment strategies. A notable development is employing deep learning techniques to predict tumor and immune phenotypes from histological images, demonstrating computational biomarkers' potential in precision oncology [52].

The discovery of extracellular matrix (ECM)-derived bioactive fragments as biomarkers provides insights into the tumor microenvironment's role in cancer progression, offering diagnostic and prognostic value. These fragments emphasize ECM components' importance in biomarker discovery and their therapeutic implications in personalized medicine. Additionally, ratiometric sensors for real-time monitoring of tumor microenvironment parameters are emerging as novel tools for early cancer diagnosis and treatment strategy optimization [12].

Emerging trends in biomarker research emphasize integrating biological networks with gene expression data, facilitating novel biomarker identification and enhancing our understanding of cancer's



Figure 4: This figure illustrates the hierarchical structure of biomarkers in personalized medicine, highlighting key areas such as patient stratification, biomarker selection, and clinical trials. Each category includes significant advancements and methodologies that contribute to the field, emphasizing genomic data utilization, feature selection methods, and the integration of predictive biomarkers in trial designs.

molecular mechanisms. This integrative approach improves the identification of critical molecular targets and pathways, leveraging predictive biomarker discovery and multimodal data integration, ultimately advancing targeted therapies tailored to individual patient profiles in precision oncology [70, 71, 19, 72, 73]. Moreover, multi-task learning approaches show significant improvements in predicting low-prevalence molecular alterations, opening new directions for biomarker research.

Developing ensemble models for predicting cancer types from biomarkers, particularly in imbalanced datasets, offers robust solutions for handling complex biomarker data, enhancing cancer classification accuracy and reliability. Future research should prioritize enhancing methodologies like the Biomarker Optimal Segmentation System (BOSS) to accommodate simultaneous analysis of multiple biomarkers, rigorously validating their effectiveness across diverse datasets. This approach is critical for advancing precision medicine, enabling optimal cutoff value identification for continuous biomarkers that differentiate patient subgroups with distinct clinical outcomes. Integrating BOSS with predictive biomarker discovery techniques can minimize false discovery rates, improving resource allocation for follow-up experiments and enhancing patient outcomes. Tools like the BOSS R package and the uniCATE R package will facilitate these advancements in biomarker analysis and treatment rule estimation [53, 72].

Integrating predictive imaging biomarkers through advanced models such as iCATE significantly enhances predictive accuracy, evidenced by their ability to identify imaging features forecasting individual treatment responses. This validation underscores these biomarkers' potential to refine treatment decision-making processes in clinical practice, advancing personalized medicine and improving patient outcomes [19, 72, 58, 74, 59]. Employing causality measures for biomarker selection further emphasizes the importance of relevant biomarker selection, enhancing diagnostic performance, especially when fewer biomarkers are available.

5 Organ-Specific Transfer and Metastasis

Examining organ-specific transfer and metastasis is crucial for understanding cancer progression, influenced by both malignant cell transformation and the tumor microenvironment (TME). The TME plays a significant role in shaping metastatic behavior through its interactions with various cellular and molecular components, essential for elucidating cancer cell dissemination pathways and secondary tumor establishment. The following subsection explores the TME's contributions to organ-specific transfer, emphasizing its importance in metastasis.

5.1 Role of Tumor Microenvironment in Organ-Specific Transfer

The TME significantly affects organ-specific transfer of cancer cells, impacting metastatic spread to distant organs by modulating cellular and molecular components. Lymphangiogenesis within the TME is crucial for cancer cell dissemination, as seen in cervical carcinoma, where new lymphatic vessels provide pathways for migration, suggesting therapeutic potential in targeting lymphangiogenesis

[75]. Detecting organ-specific transfer is challenging due to low tumor-to-nontumor ratios in lymph node tissues, complicating annotation and detection method effectiveness [76]. The immune and stromal components of the TME influence prognosis and treatment responses, as demonstrated in lung adenocarcinoma (LUAD), by creating a pro-metastatic niche that supports cancer cell survival and dissemination [56].

Hypoxia within the TME further complicates understanding exosome roles in organ-specific metastasis due to its effects on exosome release and interactions with target cells [12]. TME interactions are crucial for predicting neoadjuvant chemotherapy (NAC) responses, highlighting the need for advanced predictive models encapsulating TME complexity [13]. Homeostatic pressure within the TME contributes to metastasis inefficiency, as only a fraction of cancer cells form macroscopic tumors, emphasizing the TME's regulatory role in cancer cell dynamics and its therapeutic potential [77]. The TopoTxR method illustrates TME's significance in predicting organ-specific transfer by analyzing surrounding parenchyma, providing insights into factors influencing metastatic spread [11].

5.2 Mechanisms of Collective Cell Migration

Collective cell migration is fundamental in cancer metastasis, characterized by the coordinated movement of cancer cells as cohesive groups. In breast cancer, hierarchical gene expression regulates collective dissemination, enabling leader and follower cells to contribute uniquely to migratory dynamics [78]. Interactions between leader and follower cells determine migration rates and invasiveness, particularly in narrow, flexible channels where mechanical constraints affect movement [79]. Spatial organization within migrating clusters facilitates communication and coordination, enhancing tissue invasion.

As illustrated in Figure 5, the key mechanisms of collective cell migration encompass hierarchical gene expression, mechanical interactions, and chemotactic responses. Each of these categories significantly influences the dynamics of cancer cell migration, ultimately contributing to metastasis and tissue invasion. Chemoattractant distribution within the tumor microenvironment (TME) influences collective cell migration, with chemotactic responses governed by complex cell-chemoattractant interactions, necessitating sophisticated modeling approaches [80]. Cells' ability to sense and respond to chemical signals directs collective movement towards favorable metastatic niches. Aligning movements with neighboring cells is vital for forming motile clusters within tumors, enhancing migration and enabling deeper tissue penetration [81]. This alignment underscores the importance of mechanical interactions in collective migration.



Figure 5: This figure illustrates the key mechanisms of collective cell migration, highlighting hierarchical gene expression, mechanical interactions, and chemotactic responses. Each category influences the dynamics of cancer cell migration, contributing to metastasis and tissue invasion.

5.3 Challenges in Modeling and Predicting Metastasis

Modeling and predicting cancer metastasis is challenging due to biological system complexity and current methodology limitations. Accurately identifying and quantifying disseminated cancer cells capable of initiating metastases is complicated by dynamic tumor genomic changes and intricate metastatic cascade interactions [27]. Current approaches rely on selective sampling and pathologist input, constraining interpretability and effectiveness, necessitating multimodal integration [55]. Table

Benchmark	Size	Domain	Task Format	Metric
RNMT-PanCancer[23]	20,000	Oncology	Survival Analysis	Cox regression, Kaplan-Meier
TME-Analyzer[82]	63	Oncology	Image Analysis	Concordance with inForm and QuPath
CRC-ICM[83]	1,756	Pathology	Image Classification	Accuracy, F1-score
BCC[84]	462	Biochemistry	Clustering	Survival Rate, Clustering Validity Index

Table 1: This table presents a selection of representative benchmarks used in the study of cancer metastasis modeling and prediction. It includes details on the benchmark name, dataset size, domain, task format, and the metrics employed for evaluation. Such benchmarks are crucial for assessing the effectiveness of predictive models in oncology, pathology, and biochemistry.

1 provides an overview of representative benchmarks that highlight the diverse approaches and metrics used in the study of cancer metastasis modeling and prediction.

Predictive model effectiveness depends on input data quality and completeness, highlighting challenges in accurately modeling metastasis [85]. Existing methods' limitations, particularly regarding treatment effects for biomarker-positive patients, complicate outcome predictions [1]. The absence of comprehensive mutational pattern databases and incomplete understanding of hallmark networks restrict predictive genomics potential.

Machine learning models offer promise but face significant data-related hurdles, including overreliance on retrospective studies with limited datasets, leading to overfitting and lack of generalizability. Deep neural networks' lack of explainability further hinders clinical interpretation, creating barriers to effective application in clinical settings. The main challenge remains the lack of multimodal integration, often dependent on selective sampling and requiring pathologist input, limiting interpretability and effectiveness [55].

Challenges in measuring and quantifying metastatic process aspects, particularly dynamic tumor genomic changes and complex metastatic cascade interactions, impede predictive modeling advancements [27]. Addressing these challenges requires advancements in computational models, diverse data type integration, and deeper understanding of underlying biological mechanisms to enhance prediction accuracy and reliability in cancer metastasis.

6 Molecular Pathways in Cancer Progression

6.1 Molecular Pathways and Metabolic Reprogramming

Molecular pathways are pivotal in cancer progression, driving metabolic reprogramming that supports cancer cell survival and proliferation. Alterations in glycolysis and mitochondrial functions enable cancer cells to adapt to various environments, fulfilling energetic and biosynthetic needs and showcasing metabolic flexibility [75]. Theoretical frameworks on epithelial-mesenchymal transition (EMT) illustrate its role in metastasis, with feedback loops involving transcription factors and miRNAs enhancing metastatic potential [86]. Partial EMT as a stable phenotype highlights its dual role in tissue repair and disease progression [36].

As illustrated in Figure 6, the key molecular pathways involved in cancer progression are highlighted, focusing on metabolic reprogramming, EMT, and interactions with the tumor microenvironment. This figure underscores the alterations in glycolysis and mitochondrial functions, the role of partial EMT in metastasis, and the significance of TME-driven lymphangiogenesis and Rho-signaling pathways.

Tumor cell interactions with the microenvironment, particularly vasculature, are crucial for these pathways. In cervical carcinoma, TME-driven lymphangiogenesis necessitates targeting these pathways for therapeutic interventions [75]. Rho-signaling pathways significantly influence cell morphodynamics, affecting shape and movement, critical for cancer progression [2]. Advanced modeling techniques reveal non-linear gene interaction structures, emphasizing mechanical interactions' role in invasion dynamics [62]. Network entropy indicates early-stage cancer cell plasticity, diminishing as the disease progresses, supporting adaptation theories within molecular networks [36].



Figure 6: This figure illustrates the key molecular pathways involved in cancer progression, focusing on metabolic reprogramming, epithelial-mesenchymal transition (EMT), and interactions with the tumor microenvironment. It highlights alterations in glycolysis and mitochondrial functions, the role of partial EMT in metastasis, and the significance of TME-driven lymphangiogenesis and Rho-signaling pathways.

6.2 Tumor-Immune Interactions and Pathway Analysis

Tumor-immune interactions, governed by complex molecular pathways, are crucial in cancer progression. The immune system's dual role in cancer cell recognition and elimination, alongside tumor growth facilitation through immune evasion, highlights these interactions' complexity. A theoretical framework using mass conservation laws and molecule classification elucidates the balance between immune surveillance and escape [87]. TME heterogeneity, driven by genetic and epigenetic factors, impacts tumor-immune interactions, influencing immunotherapy effectiveness [88]. EMT dynamics, governed by bistable switches, further complicate these interactions by affecting cellular phenotypes and immune recognition [89].

Pathway analysis reveals TME's significant impact on immune cell behavior, modulating pathways that can promote or inhibit immune responses. Interactions among TME components, such as tumor-associated macrophages, cancer-associated fibroblasts, and extracellular matrix elements, play crucial roles in tumor progression, immune evasion, and metastasis [8, 3, 10]. Cytokines, chemokines, and growth factors in the microenvironment shape the immune landscape, affecting cell infiltration, activation, and exhaustion. Understanding these pathways is vital for developing strategies to enhance the immune system's capacity to target cancer cells effectively.

6.3 Metabolic Pathways and Cancer Invasion

Metabolic pathways are integral to cancer cell invasion and metastasis, driving phenotypic alterations that enable adaptation in diverse microenvironments. These pathways support growth, apoptosis evasion, and migration, essential for successful metastasis. However, current methodologies struggle to capture the full scope of these pathways, particularly those not visible in histopathological images, limiting molecular pathway assessments in cancer progression [90]. The complexity of metabolic interactions is compounded by challenges in integrating individual pathways and their cross-talk within predictive models [91]. Addressing this requires a comprehensive approach considering the interplay between various pathways and their collective impact on cancer dynamics.

The TME significantly influences cancer cell metabolism, with mechanical interactions playing a pivotal role in modulating behavior, crucial for understanding migration patterns and developing anti-metastatic strategies [79]. Physical constraints imposed by the TME can alter cellular metabolism, affecting invasive potential. Advanced modeling techniques, such as the dynamic cluster field method, accurately capture chemoattractant transport dynamics and their influence on collective cell migration [80]. These models provide insights into how metabolic pathways and chemotactic signals drive invasion, emphasizing the need for integrative approaches combining biological, physical, and clinical knowledge [92].

Developing predictive models linking genotypes to regulatory and cellular phenotypes is crucial for understanding metabolic pathways' role in cancer progression [93]. These models offer a pathway-based perspective that enhances predictive capabilities for clinical outcomes and guides therapeutic

interventions. Dynamic changes in gene co-expression networks underscore molecular pathways' significance in understanding cancer progression [94].

7 Predictive Modeling in Cancer Research

Category	Feature	Method
Hybrid and Nonparametric Modeling Approaches	Physical and Biological Systems Modeling	CPM[81], IS3D-SMB[44]
	Statistical and Monitoring Methods	3D-APCM-PS[43]
	Optimization and Regularization	L1-NR[85], RSGP[95]
	Knowledge Representation	XAI[66], DIGME[45], ONO-KG[73]
Deep Learning and Image Analysis	Scale-Sensitive Techniques	LSM[41]
Integration of Biophysical and Biochemical Models	Biophysical and Biochemical Integration	EABM[8]
Machine Learning and Statistical Techniques	Bayesian Methods	JMTELD[96]
	Interactive and Visualization Techniques	iGPSe[65]
	Neural Network Enhancements	ML-FRET[34]
	Multi-Task Learning Strategies	PMBT[56]
Multimodal and Multiscale Data Integration	Comprehensive Data Integration	MC-TMB[97], PDNI[98]

Table 2: This table provides a comprehensive overview of various methodologies employed in predictive cancer modeling. It categorizes methods into hybrid and nonparametric modeling approaches, deep learning and image analysis, integration of biophysical and biochemical models, machine learning and statistical techniques, and multimodal and multiscale data integration. Each category lists specific features and methods, highlighting the diverse techniques used to enhance predictive accuracy and address the complexities of cancer progression.

Predictive modeling in cancer research requires exploring methodologies that enhance understanding of cancer dynamics. Table 3 presents a detailed summary of the diverse methodologies utilized in predictive cancer modeling, underscoring the integration of various approaches to enhance understanding and prognostic accuracy in cancer research. This section delves into hybrid and nonparametric approaches, which improve predictive accuracy and address cancer progression complexities.

7.1 Hybrid and Nonparametric Modeling Approaches

Hybrid and nonparametric approaches are pivotal in predictive cancer modeling, offering frameworks that address the disease's complexity. Hybrid models, which integrate diverse methodologies, enhance predictive accuracy by combining hypergraph theory with machine learning [73]. Explainable Artificial Intelligence (XAI) models merge machine learning with explainability to improve prognostic accuracy and illuminate the immune landscape's role in therapy [66]. The RSGP method exemplifies this by predicting breast cancer outcomes through grid search and machine learning [95].

Nonparametric approaches, adaptable to heterogeneous cancer data, avoid predefined parametric forms, allowing models to adjust to data characteristics. L1 regularization in a ranking-based approach identifies clinically relevant covariates for risk stratification, demonstrating nonparametric techniques' utility [85]. The Cellular Potts Model (CPM) simulates cell dynamics and interactions using energy minimization principles [81].

Spatiotemporal measurement techniques, capturing cytokine dynamics, enrich hybrid and nonparametric models, enhancing understanding of cancer progression and treatment responses [44]. Continuous pH monitoring in 3D pancreatic cancer models provides valuable data for predictive modeling regarding treatment efficacy [43].

The Joint Model of Time-to-Event and Longitudinal Data (JMTELD) combines time-to-event data with longitudinal measurements, offering a comprehensive framework for cancer outcome prediction [96]. Applying causal inference frameworks to machine learning improves bias handling and dataset shift management, enhancing model generalization [99].

Future research could automate the DIGME process for higher throughput and incorporate microfabrication techniques for improved geometric control [45]. Enhanced agent-based models could simulate macrophage interactions and their effects on tumor growth, categorizing macrophages into M0, M1, and M2 behaviors, offering deeper insights into the tumor microenvironment [8].

7.2 Deep Learning and Image Analysis

Deep learning has transformed cancer image analysis, enabling accurate clinical outcome predictions through complex pattern extraction in histopathological data. Deep neural networks (DNNs) excel in learning hierarchical data representations, capturing critical sub-cellular and macro-cellular features [41]. Optimal accuracy in DNNs is achieved with resolvable feature lengths (RFLs) under 1.2 microns and maximum feature lengths (MFLs) exceeding 41 microns, emphasizing scale importance in image analysis.

Integrating DNNs with advanced imaging techniques enhances tumor characteristic identification, facilitating patient stratification based on predicted treatment responses. These predictive models are effective across oncology applications, including tumor heterogeneity assessment and biomarker identification, enhancing clinical decision-making and improving patient outcomes through personalized therapies [70, 19, 72, 69, 55]. DNNs' capacity to process vast datasets and extract insights is revolutionizing cancer diagnostics and prognostics.

As illustrated in Figure 7, the hierarchical structure of deep learning applications in cancer image analysis underscores the pivotal roles of DNNs in imaging, the development of predictive models, and advancements in multimodal learning techniques. Attention mechanisms within DNN architectures improve model interpretability, enhancing understanding of features driving clinical outcomes. This interpretability fosters clinician trust and facilitates deep learning model integration into clinical workflows. As cancer research evolves, enhancing deep learning methodologies and integrating diverse data modalities is expected to boost predictive accuracy and clinical relevance. Recent advancements in multimodal deep learning combine data types—from gigapixel whole slide images to RNA sequencing and mutation data—enabling identification of prognostic features correlating with patient outcomes across cancer types. This approach supports risk stratification and novel biomarker discovery, contributing to personalized and effective cancer care [19, 100, 55].



Figure 7: This figure illustrates the hierarchical structure of deep learning applications in cancer image analysis, highlighting the roles of DNNs in imaging, the development of predictive models, and advancements in multimodal learning techniques.

7.3 Integration of Biophysical and Biochemical Models

Integrating biophysical and biochemical models in cancer research advances understanding of tumor dynamics and therapeutic strategies. This approach merges model strengths, creating a robust framework for analyzing intricate interactions within the tumor microenvironment (TME), which influences tumor initiation, growth, and therapeutic responses [3, 7, 48]. Biophysical models focus on mechanical properties and physical interactions, while biochemical models emphasize molecular pathways and signaling networks driving cancer progression.

Technological advancements in 'omics' approaches identify potential therapeutic targets within the TME, highlighting the importance of integrating data-rich methodologies into biophysical and biochemical models [101]. Incorporating genomic, proteomic, and metabolomic data deepens understanding of cancer's molecular underpinnings and identifies key therapeutic intervention pathways.

This model integration simulates and predicts tumor behavior under various conditions, providing insights into potential therapeutic strategy outcomes. Capturing complex interactions and feedback

loops within the TME enables predictions of tumor behavior based on macrophage modulation [8]. Such capabilities are crucial for developing personalized treatment plans considering each patient's tumor characteristics and microenvironment.

Integrating biophysical and biochemical models enhances understanding of mechanical forces and molecular signals interplay, shaping cancer cell behavior during invasion and metastasis. These models explore how factors like cell adhesion, ECM interactions, and mechanical constraints influence cancer cell dynamics, shedding light on mechanisms driving tumor progression and potential therapeutic strategies [79, 102, 103, 104, 105]. This holistic approach provides a comprehensive view of factors driving tumor growth and metastasis, paving the way for novel therapies targeting both physical and molecular aspects of cancer.

7.4 Graph-Based and Network Models

Graph-based and network models are powerful tools for understanding complex interactions driving cancer progression. These models create a framework for depicting interrelationships among biological entities, enabling investigation of molecular networks driving cancer development and metastasis. This facilitates biomarker and therapeutic target identification through integrating knowledge graphs, gene regulatory networks, and advanced analytical methods. Insights from cancer stem cell biology, epithelial-mesenchymal transition processes, and dynamic interactions of cancer stem cell markers enhance understanding of mechanisms underlying cancer progression and treatment resistance [71, 106, 107, 73, 108]. By capturing connectivity and dynamics, graph-based models identify key nodes and pathways as therapeutic targets.

Graph-based models integrate diverse data types, including genomic, transcriptomic, and proteomic data, constructing comprehensive interaction networks. This integrative approach facilitates novel biomarker identification and elucidates molecular mechanisms driving cancer progression. In colorectal cancer, these models highlight immune markers' importance and interactions in shaping patient outcomes [83]. Analyzing these interactions enables predictive model development, informing treatment strategies and improving patient prognosis.

Network models explore cancer cells' dynamic behavior within the TME. Simulating interactions between cancer cells and TME components, including stromal and immune cells, provides insights into immune evasion and tumor growth mechanisms. Detailed examinations of factors like macrophage behavior and immune cell localization impact tumor proliferation and therapeutic strategies aimed at enhancing immune infiltration, particularly in immunologically cold solid tumors [8, 47, 3]. Understanding these dynamics is crucial for developing therapies targeting the TME and disrupting the supportive niche facilitating cancer progression.

Future research could expand graph-based models to include additional immune markers and interactions, enhancing predictive power in clinical settings [83]. By refining these models and incorporating new data sources, researchers can gain deeper insights into complex networks driving cancer progression, informing targeted therapy development and improving patient outcomes.

7.5 Machine Learning and Statistical Techniques

Machine learning and statistical techniques are integral to predictive cancer modeling, providing robust frameworks for analyzing complex datasets and enhancing prognostic accuracy. These techniques identify distinct patient subgroups that traditional models may overlook by modeling complex relationships between disease outcomes and various covariates [69]. Integrating machine learning algorithms with visualization techniques, exemplified by platforms like iGPSe, facilitates patient stratification by revealing underlying patterns within cancer data [65]. This stratification is crucial for tailoring therapeutic interventions to individual patients.

Advanced computational techniques, such as those used in FRET imaging, improve the accuracy of analyzing RhoA activities, demonstrating machine learning's role in refining imaging methodologies for cancer research [34]. Bayesian inference via Hamiltonian Monte Carlo enables parameter estimation while accommodating individual-specific change points, showcasing statistical methods' adaptability in capturing cancer's dynamic nature [96].

Evaluating predictive models often involves metrics like the area under the receiver operating characteristic (AUROC) curve, measuring model accuracy across cancer types [56]. Machine learning

classifiers, including logistic regression, random forest, deep neural networks, gradient-boosted trees, and XGBoost, improve cancer outcome predictions by leveraging various algorithm strengths. Understanding causal relationships between variables can lead to more robust machine learning models in diagnostics [99].

Incorporating statistical techniques, such as the IPR method, quantifies structural disorder in cancer cells, offering new avenues for predictive modeling. This approach provides a quantitative measure of heterogeneity within cancer cell populations, contributing to a comprehensive understanding of cancer dynamics. Integrating Monte Carlo and smoothing methods with GPU computing significantly enhances the speed and accuracy of addressing complex optimization challenges in clinical trials. This advancement enables real-time assessments of treatment efficacy, particularly in personalized medicine, where identifying optimal patient subsets based on biomarkers is crucial. Our innovative computational approach not only enhances clinical trial design by effectively incorporating high-dimensional biomarker data but also demonstrates scalability for larger datasets, achieving accuracy improvements up to 133 times faster than conventional methods. This capability is essential for bridging research findings with practical drug development, ultimately leading to more effective and individualized treatment strategies [67, 69, 68, 59, 95].

7.6 Multimodal and Multiscale Data Integration

Integrating multimodal and multiscale data has emerged as a pivotal approach in enhancing predictive cancer modeling, offering a comprehensive understanding of tumor dynamics and improving model accuracy. The MC-TMB framework exemplifies this integration by leveraging multi-scale data to enhance tumor mutational burden (TMB) status prediction accuracy, underscoring data integration's critical role in cancer research [97]. This approach incorporates diverse data types, such as genomic, transcriptomic, and proteomic information, providing a holistic view of the tumor microenvironment (TME) and its influence on cancer progression.

Advanced imaging techniques, including optical and magnetic resonance imaging, complement this integration by offering high specificity and sensitivity in visualizing the TME [38]. The development of 3D in vitro models enables real-time observation of tumor-vasculature dynamics under physiological flow conditions, significantly contributing to predictive modeling by providing insights into interactions between cancer cells and their environment [109].

Future research should focus on enhancing predictive model generalizability across different datasets, improving model explainability, and further exploring multimodal data integration to achieve enhanced predictive accuracy [64]. Integrating pathway analysis with gene regulatory network inference represents an emerging trend promising to elucidate complex interactions within cancer systems, paving the way for more robust predictive models [98].

Additionally, refining the dimensionality reduction process and exploring its applicability to complex datasets can further enhance multimodal data integration, enabling researchers to capture nuanced interactions within the TME and improve cancer model predictive power [110]. By embracing these advancements, researchers can continue to push the boundaries of cancer research, ultimately leading to more precise and personalized therapeutic strategies.

7.7 Emerging Trends and Future Directions

Emerging trends in predictive modeling and cancer research emphasize integrating advanced computational techniques with biological insights to enhance cancer understanding and treatment. Developing non-linear models for feature selection is a promising direction, aiming to improve stability and facilitate novel biomarker discovery within diverse biological networks [61]. This approach highlights leveraging complex interactions within the TME to identify key molecular targets for therapeutic intervention.

Enhancing predictive models through advanced data integration techniques is essential for capturing complex interactions within the TME, enabling nuanced understanding of tumor heterogeneity and informing clinical decision-making in precision oncology. This approach facilitates identifying predictive imaging biomarkers and patient subgroups while addressing challenges posed by diverse tumor characteristics, ultimately contributing to improved outcomes in cancer assessment, diagnosis, and treatment [59, 69, 19]. It includes utilizing advanced imaging techniques and longitudinal data

collection to track metastatic lesions and tumor behavior over time. By enhancing data granularity, researchers can develop more precise models reflecting cancer progression's multifaceted nature.

Future research should focus on exploiting vulnerabilities in cancer cells' plastic states, offering new therapeutic avenues. Targeting molecular mechanisms underlying metastasis-initiating cell (MIC) plasticity may improve therapeutic responses and overcome resistance mechanisms. Investigating combination therapies targeting multiple molecular pathways could yield synergistic effects, enhancing treatment efficacy and improving patient outcomes. This approach aligns with recent precision oncology advancements, emphasizing integrating multimodal data to better understand tumor heterogeneity and develop tailored treatment strategies. Insights from genomic profiling and drug response patterns identified through comprehensive studies like the Cancer Genome Project can help identify effective therapeutic biomarkers and predict drug synergies, ultimately leading to more effective treatment regimens for diverse patient populations [70, 19, 1].

Integrating genomic data with clinical outcomes emerges as a transformative approach in personalized cancer treatment, leveraging multimodal data integration techniques to enhance tumor heterogeneity understanding, improve clinical decision-making, and facilitate identifying predictive biomarkers for drug sensitivity, resistance, and patient prognosis across cancer types. This comprehensive strategy aids in tailoring targeted therapies to individual patients while addressing significant challenges in cancer management, such as predicting clonal evolution and optimizing treatment pathways based on unique genomic profiles [70, 93, 19, 55]. Liquid biopsies offer a minimally invasive method for monitoring metastasis and treatment responses in real-time, providing valuable insights into tumor dynamics and resistance patterns. Refining models to incorporate complex TME interactions and validate predictions against clinical data is essential for translating research findings into clinical practice.

In breast cancer research, there is a growing emphasis on refining predictive models for shorter-term outcomes and incorporating additional clinical features to enhance prognostic capabilities. The focus on personalized medicine is increasingly reflected in developing targeted therapies designed to address the distinct genetic and phenotypic characteristics of individual tumors, as evidenced by advances in predictive genomics and the Cancer Genome Project. These initiatives leverage genome sequencing data to identify unique drug targets, anticipate drug resistance, and understand tumor microenvironment interactions, ultimately enhancing the precision and efficacy of cancer treatments [70, 93, 7].

Emerging trends in precision oncology highlight the necessity for a multidisciplinary approach that synergistically combines advanced technologies, innovative therapeutic strategies, and comprehensive data analysis. This integration is essential for effectively addressing tumor heterogeneity complexities, improving clinical decision-making, and enhancing robust biomarker identification. Recent advancements in multimodal data integration and deep learning techniques illustrate the potential for developing personalized treatment protocols that leverage diverse data sources, facilitating early diagnosis, prognosis, and biomarker discovery. As the field evolves, incorporating methods that account for variability across clinical trials and utilizing generative AI frameworks to streamline biomarker identification will drive the future of personalized medicine [52, 54, 19, 55]. By continuing to push the boundaries of cancer research, these efforts aim to improve cancer diagnosis, treatment, and patient outcomes, ultimately advancing oncology.

Feature	Hybrid and Nonparametric Modeling Approaches	Deep Learning and Image Analysis	Integration of Biophysical and Biochemical Models
Model Type	Hybrid/nonparametric	Deep Learning	Integrated
Primary Application	Predictive Accuracy	Image Analysis	Tumor Dynamics
Key Feature	Hypergraph Integration	Hierarchical Data Representation	Molecular Pathway Emphasis

Table 3: This table provides a comparative analysis of three distinct modeling approaches in predictive cancer research: Hybrid and Nonparametric Modeling, Deep Learning and Image Analysis, and Integration of Biophysical and Biochemical Models. Each approach is evaluated based on model type, primary application, and key features, highlighting their unique contributions to enhancing predictive accuracy, image analysis, and understanding of tumor dynamics.

8 Conclusion

The exploration of the tumor microenvironment (TME) reveals its pivotal influence on cancer progression, metastasis, and therapeutic resistance. By modulating immune responses and facilitating

tumor growth, the TME plays a crucial role in organ-specific metastasis through processes like lymphangiogenesis and collective cell migration. A deep understanding of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT) is fundamental to devising effective cancer therapies, as these elements are central to the metastatic cascade. Additionally, metabolic reprogramming and tumor-immune interactions emerge as promising targets for therapeutic intervention against metastasis.

Biomarkers have gained prominence in cancer diagnosis, prognosis, and treatment prediction, supported by advanced computational and imaging methodologies. Frameworks such as WGTDA have demonstrated potential in robust biomarker discovery, uncovering significant gene signatures more effectively than traditional approaches. Moreover, models like PMBT have shown efficacy in predicting overall survival and immunotherapy responses in lung adenocarcinoma (LUAD) patients, indicating their prognostic value across various datasets.

The integration of multimodal and multiscale data in predictive modeling enhances the comprehension of tumor dynamics, with nonparametric and hybrid approaches offering potential improvements in diagnostic precision and treatment strategies. Furthermore, inter-organ and intra-organ data augmentations contribute valuable methodologies for bolstering model robustness and accuracy in metastasis detection.

Future research should focus on elucidating the molecular pathways involved in metastasis, advancing targeted therapies, and examining the roles of the immune system and microenvironment in cancer progression. Understanding the dynamics of non-genetic heterogeneity is crucial for informing therapeutic strategies, as it represents a critical adaptive trait in cancer evolution. The potential of the IPR technique for broader applications in cancer treatment assessment merits further investigation across various cancer types. Additionally, local expression correlation patterns offer valuable insights for identifying genes and pathways implicated in metastasis, emphasizing the need for continued exploration in this area.

References

[1] Lorna Wheaton, Dan Jackson, and Sylwia Bujkiewicz. Bayesian meta-analysis for evaluating treatment effectiveness in biomarker subgroups using trials of mixed patient populations, 2023.

[2] David Basanta, Haralambos Hatzikirou, and Andreas Deutsch. Studying the emergence of invasiveness in tumours using game theory, 2008.

[3] Christiana M Neophytou, Myrofora Panagi, Triantafyllos Stylianopoulos, and Panagiotis Papageorgis. The role of tumor microenvironment in cancer metastasis: Molecular mechanisms and therapeutic opportunities. *Cancers*, 13(9):2053, 2021.

[4] Nicolas A Giraldo, Rafael Sanchez-Salas, J David Peske, Yann Vano, Etienne Becht, Florent Petitprez, Pierre Validire, Alexandre Ingels, Xavier Cathelineau, Wolf Herman Fridman, et al. The clinical role of the tme in solid cancer. *British journal of cancer*, 120(1):45–53, 2019.

[5] Maria Teresa Bilotta, Antonella Antignani, and David J Fitzgerald. Managing the tme to improve the efficacy of cancer therapy. *Frontiers in immunology*, 13:954992, 2022.

[6] Ralf Hass, Juliane von der Ohe, and Hendrik Ungefroren. The intimate relationship among emt, met and tme: At (ransdifferentiation) e (nhancing) m (ix) to be exploited for therapeutic purposes. *Cancers*, 12(12):3674, 2020.

[7] Catarina Roma-Rodrigues, Rita Mendes, Pedro V Baptista, and Alexandra R Fernandes. Targeting tumor microenvironment for cancer therapy. *International journal of molecular sciences*, 20(4):840, 2019.

[8] Mobina Tousian, Christian Solis Calero, and Julio Cesar Perez Sansalvador. Immune cells interactions in the tumor microenvironment, 2024.

[9] Sylvie Brassart-Pasco, Stéphane Brézillon, Bertrand Brassart, Laurent Ramont, Jean-Baptiste Oudart, and Jean Claude Monboisse. Tumor microenvironment: extracellular matrix alterations influence tumor progression. *Frontiers in oncology*, 10:397, 2020.

[10] Maonan Wang, Jingzhou Zhao, Lishen Zhang, Fang Wei, Yu Lian, Yingfeng Wu, Zhaojian Gong, Shanshan Zhang, Jianda Zhou, Ke Cao, et al. Role of tumor microenvironment in tumorigenesis. *Journal of Cancer*, 8(5):761, 2017.

[11] Fan Wang, Saarthak Kapse, Steven Liu, Prateek Prasanna, and Chao Chen. Topotxr: A topological biomarker for predicting treatment response in breast cancer, 2021.

[12] Guangpeng He, Xueqiang Peng, Shibo Wei, Shuo Yang, Xinyu Li, Mingyao Huang, Shilei Tang, Hongyuan Jin, Jiaxing Liu, Sheng Zhang, et al. Exosomes in the hypoxic tme: from release, uptake and biofunctions to clinical applications. *Molecular Cancer*, 21(1):19, 2022.

[13] Qiang Li, George Teodoro, Yi Jiang, and Jun Kong. Nacnet: A histology context-aware transformer graph convolution network for predicting treatment response to neoadjuvant chemotherapy in triple negative breast cancer, 2024.

[14] Xiaoli Shi, Xinyi Wang, Wentao Yao, Dongmin Shi, Xihuan Shao, Zhengqing Lu, Yue Chai, Jinhua Song, Weiwei Tang, and Xuehao Wang. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. *Signal transduction and targeted therapy*, 9(1):192, 2024.

[15] Tumor microenvironment: rec vari.

[16] Zhihui Wang, Christina M. Birch, and Thomas S. Deisboeck. Cross-scale sensitivity analysis of a non-small cell lung cancer model: Linking molecular signaling properties to cellular behavior, 2007.

[17] Bo Ren, Ming Cui, Gang Yang, Huanyu Wang, Mengyu Feng, Lei You, and Yupei Zhao. Tumor microenvironment participates in metastasis of pancreatic cancer. *Molecular cancer*, 17:1–15, 2018.

[18] Hanxiao Xu, Mengke Niu, Xun Yuan, Kongming Wu, and Aiguo Liu. Cd44 as a tumor biomarker and therapeutic target. *Experimental hematology & oncology*, 9:1–14, 2020.

[19] Huajun Zhou, Fengtao Zhou, Chenyu Zhao, Yingxue Xu, Luyang Luo, and Hao Chen. Multimodal data integration for precision oncology: Challenges and future directions, 2024.

[20] Jawad Fares, Mohamad Y Fares, Hussein H Khachfe, Hamza A Salhab, and Youssef Fares. Molecular principles of metastasis: a hallmark of cancer revisited. *Signal transduction and targeted therapy*, 5(1):28, 2020.

[21] Joan Massague and Karuna Ganesh. Metastasis-initiating cells and ecosystems. *Cancer discovery*, 11(4):971–994, 2021.

[22] Boire priscilla brastianos liv.

[23] Shuqiang Huang, Cuiyu Tan, Jinzhen Zheng, Zhugu Huang, Zhihong Li, Ziyin Lv, and Wanru Chen. Integrative pan-cancer analysis of rnmt: a potential prognostic and immunological biomarker, 2024.

[24] Dalia Barkley, Reuben Moncada, Maayan Pour, Deborah A Liberman, Ian Dryg, Gregor Werba, Wei Wang, Maayan Baron, Anjali Rao, Bo Xia, et al. Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment. *Nature genetics*, 54(8):1192–1201, 2022.

[25] Chao-Nan Qian, Yan Mei, and Jian Zhang. Cancer metastasis: issues and challenges. *Chinese journal of cancer*, 36:1–4, 2017.

[26] Cancer metastasis - tricks of th.

[27] Jacob G. Scott, Philip Gerlee, David Basanta, Alexander G. Fletcher, Philip K. Maini, and Alexander RA Anderson. Mathematical modeling of the metastatic process, 2013.

[28] Sounak Sadhukhan and S. K. Basu. Tumour induced angiogenesis and its simulation, 2019.

[29] Pascal R. Buenzli, Peter Pivonka, Bruce S. Gardiner, and David W. Smith. Modelling the anabolic response of bone using a cell population model, 2012.

[30] Christopher Z. Eddy, Xinyao Wang, Fuxin Li, and Bo Sun. The morphodynamics of 3d migrating cancer cells, 2019.

[31] Jorge Escribano, Michelle B. Chen, Emad Moeendarbary, Xuan Cao, Vivek Shenoy, Jose Manuel Garcia-Aznar, Roger D. Kamm, and Fabian Spill. Balance of mechanical forces drives endothelial gap formation and may facilitate cancer and immune-cell extravasation, 2018.

[32] M. Ali Al-Radhawi and Eduardo D. Sontag. Analysis of a reduced model of epithelial-mesenchymal fate determination in cancer metastasis as a singularly-perturbed monotone system, 2020.

[33] Zuzanna Szymańska, Mirosław Lachowicz, Nikolaos Sfakianakis, and Mark A. J. Chaplain. Mathematical modelling of cancer invasion: Phenotypic transitioning provides insight into multifocal foci formation, 2023.

[34] Brian CH Cheung, Louis Hodgson, Jeffrey E Segall, and Mingming Wu. Spatial and temporal dynamics of rhoa activities of single breast tumor cells in a 3d environment revealed by a machine learning-assisted fret technique, 2021.

[35] Jorge Gómez Tejeda Zañudo, M. Tyler Guinn, Kevin Farquhar, Mariola Szenk, Steven N. Steinway, Gábor Balázsi, and Réka Albert. Towards control of cellular decision-making networks in the epithelial-to-mesenchymal transition, 2019.

[36] David M. Gyurko, Daniel V. Veres, Dezso Modos, Katalin Lenti, Tamas Korcsmaros, and Peter Csermely. Adaptation and learning of molecular networks as a description of cancer development at the systems-level: Potential use in anti-cancer therapies, 2013.

[37] Tijana T. Ivancevic, Murk J. Bottema, and Lakhmi C. Jain. A theoretical model of chaotic attractor in tumor growth and metastasis, 2008.

[38] S. Prasad, A. Chandra, M. Cavo, E. Parasido, S. Fricke, Y. Lee, E. D'Amone, G. Gigli, C. Albanese, O. Rodriguez, and L. L. del Mercato. Optical and magnetic resonance imaging approaches for investigating the tumour microenvironment: state-of-the-art review and future trends, 2021.

[39] Fangliangzi Meng, Hongrun Zhang, Ruodan Yan, Guohui Chuai, Chao Li, and Qi Liu. Genomics-guided representation learning for pathologic pan-cancer tumor microenvironment subtype prediction, 2024.

[40] Zihao Chen, Jia Lu, Xing-Ming Zhao, Haiyang Yu, and Chunhe Li. Energy landscape reveals the underlying mechanism of cancer-adipose conversion with gene network models, 2023.

[41] Haowen Zhou, Steven, Lin, Mark Watson, Cory T. Bernadt, Oumeng Zhang, Ramaswamy Govindan, Richard J. Cote, and Changhuei Yang. Length-scale study in deep learning prediction for non-small cell lung cancer brain metastasis, 2024.

[42] Jihan Kim, Yu Zheng, Amani A. Alobaidi, Hanqing Nan, Jianxiang Tian, Yang Jiao, and Bo Sun. Collective ecm remodeling organizes 3d collective cancer invasion, 2019.

[43] Anna Chiara Siciliano, Stefania Forciniti, Valentina Onesto, Helena Iuele, Donatella Delle Cave, Federica Carnevali, Giuseppe Gigli, Enza Lonardo, and Loretta L. del Mercato. A 3d pancreatic cancer model with integrated optical sensors for noninvasive metabolism monitoring and drug screening, 2024.

[44] Alexander J McGhee, Eric O McGhee, Jack E Famiglietti, and W. Gregory Sawyer. In situ 3d spatiotemporal measurement of soluble biomarkers in organoid culture, 2022.

[45] Amani A. Alobaidi and Bo Sun. Probing three-dimensional collective cancer invasion with digme, 2016.

[46] Daniel Jiménez-Sánchez, Mikel Ariz, Hang Chang, Xavier Matias-Guiu, Carlos E. de Andrea, and Carlos Ortiz de Solórzano. Naronet: Discovery of tumor microenvironment elements from highly multiplexed images, 2021.

[47] Zitong Jerry Wang, Alexander M. Xu, Aman Bhargava, and Matt W. Thomson. Generating counterfactual explanations of tumor spatial proteomes to discover effective strategies for enhancing immune infiltration, 2023.

[48] Ming-Zhu Jin and Wei-Lin Jin. The updated landscape of tumor microenvironment and drug repurposing. *Signal transduction and targeted therapy*, 5(1):166, 2020.

[49] Bainan Liu, Lingli Yan, and Ming Zhou. Target selection of car t cell therapy in accordance with the tme for solid tumors. *American journal of cancer research*, 9(2):228, 2019.

[50] Abderrahim Chafik. The role of crkl in breast cancer metastasis: Insights from systems biology, 2016.

[51] Robert M Califf. Biomarker definitions and their applications. *Experimental biology and medicine*, 243(3):213–221, 2018.

[52] Wangyang Ying, Dongjie Wang, Xuanming Hu, Ji Qiu, Jin Park, and Yanjie Fu. Revolutionizing biomarker discovery: Leveraging generative ai for bio-knowledge-embedded continuous space exploration, 2024.

[53] Liuyi Lan, Xuanjin Cheng, Li Xing, and Xuekui Zhang. Boss – biomarker optimal segmentation system, 2023.

[54] Yichen Lu, Jane Fridlyand, Tiffany Tang, Ting Qi, Noah Simon, and Ning Leng. The future will be different than today: Model evaluation considerations when developing translational clinical biomarker, 2021.

[55] Richard J. Chen, Ming Y. Lu, Drew F. K. Williamson, Tiffany Y. Chen, Jana Lipkova, Muhammad Shaban, Maha Shady, Mane Williams, Bumjin Joo, Zahra Noor, and Faisal Mahmood. Pan-cancer integrative histology-genomic analysis via interpretable multimodal deep learning, 2021.

[56] Zihang Zeng, Jiali Li, Nannan Zhang, Xueping Jiang, Yanping Gao, Liexi Xu, Xingyu Liu, Jiarui Chen, Yuke Gao, Linzhi Han, Jiangbo Ren, Yan Gong, and Conghua Xie. Tumor microenvironment-based gene signatures divides novel immune and stromal subgroup classification of lung adenocarcinoma, 2019.

[57] Songhan Jiang, Zhengyu Gan, Linghan Cai, Yifeng Wang, and Yongbing Zhang. Multimodal cross-task interaction for survival analysis in whole slide pathological images, 2024.

[58] Thomas Booth, Matthew Williams, Aysha Luis, Jorge Cardoso, Ashkan Keyoumars, and Haris Shuaib. Machine learning and glioma imaging biomarkers, 2019.

[59] Shuhan Xiao, Lukas Klein, Jens Petersen, Philipp Vollmuth, Paul F. Jaeger, and Klaus H. Maier-Hein. Enhancing predictive imaging biomarker discovery through treatment effect analysis, 2024.

[60] Jessica Gliozzo. Network-based methods for outcome prediction in the "sample space", 2017.

[61] Chloé-Agathe Azencott. Network-guided biomarker discovery, 2016.

[62] Ndivhuwo Nyase, Lebohang Mashatola, Aviwe Kohlakala, Kahn Rhrissorrakrai, and Stephanie Muller. Wgtda: A topological perspective to biomarker discovery in gene expression data, 2024.

[63] Kshitij Ingale, Sun Hae Hong, Qiyuan Hu, Renyu Zhang, Bo Osinski, Mina Khoshdeli, Josh Och, Kunal Nagpal, Martin C. Stumpe, and Rohan P. Joshi. Efficient and generalizable prediction of molecular alterations in multiple cancer cohorts using he whole slide images, 2024.

[64] Heather D. Couture. Deep learning-based prediction of molecular tumor biomarkers from he: A practical review, 2022.

[65] Hao Ding, Chao Wang, Kun Huang, and Raghu Machiraju. igpse: A visual analytic system for integrative genomic based cancer patient stratification, 2014.

[66] Debaditya Chakraborty, Cristina Ivan, Paola Amero, Maliha Khan, Cristian Rodriguez-Aguayo, Hakan Başağaoğlu, and Gabriel Lopez-Berestein. Explainable artificial intelligence reveals novel insight into tumor microenvironment conditions linked with better prognosis in patients with breast cancer, 2021.

[67] Sayan Dasgupta and Ying Huang. Selecting biomarkers for building optimal treatment selection rules using kernel machines, 2019.

[68] Yitao Lu, Julie Zhou, Li Xing, and Xuekui Zhang. The optimal design of clinical trials with potential biomarker effects, a novel computational approach, 2020.

[69] Xu Gao, Weining Shen, Jing Ning, Ziding Feng, and Jianhua Hu. Addressing patient heterogeneity in disease predictive model development, 2021.

[70] Hongmei Liu and J. Sunil Rao. Precision therapeutic biomarker identification with application to the cancer genome project, 2017.

[71] Shikha Vashisht and Ganesh Bagler. An approach for the identification of targets specific to bone metastasis using cancer genes interactome and gene ontology analysis, 2012.

[72] Philippe Boileau, Nina Ting Qi, Mark J. van der Laan, Sandrine Dudoit, and Ning Leng. A flexible approach for predictive biomarker discovery, 2022.

[73] Md. Rezaul Karim, Lina Molinas Comet, Md Shajalal, Oya Deniz Beyan, Dietrich Rebholz-Schuhmann, and Stefan Decker. From large language models to knowledge graphs for biomarker discovery in cancer, 2023.

[74] James PB O'connor, Eric O Aboagye, Judith E Adams, Hugo JWL Aerts, Sally F Barrington, Ambros J Beer, Ronald Boellaard, Sarah E Bohndiek, Michael Brady, Gina Brown, et al. Imaging biomarker roadmap for cancer studies. *Nature reviews Clinical oncology*, 14(3):169–186, 2017.

[75] T. R. Fanshawe, C. M. Chapman, and T. Crick. Lymphangiogenesis and carcinoma in the uterine cervix: Joint and hierarchical models for random cluster sizes and continuous outcomes, 2016.

[76] Apostolia Tsirikoglou, Karin Stacke, Gabriel Eilertsen, and Jonas Unger. Primary tumor and inter-organ augmentations for supervised lymph node colon adenocarcinoma metastasis detection, 2021.

[77] Markus Basan, Thomas Risler, Jean-Francois Joanny, Xavier Sastre-Garau, and Jacques Prost. Homeostatic competition drives tumor growth and metastasis nucleation, 2009.

[78] Shubham Tripathi, Mohit Kumar Jolly, Wendy A. Woodward, Herbert Levine, and Michael W. Deem. Analysis of hierarchical organization in gene expression networks reveals underlying principles of collective tumor cell dissemination and metastatic aggressiveness of inflammatory breast cancer, 2017.

[79] Qiyao Peng, Fred J Vermolen, and Daphne Weihs. Physical confinement and cell proximity increase cell migration rates and invasiveness: A mathematical model of cancer cell invasion through flexible channels, 2022.

[80] Aditya Paspunurwar, Adrian Moure, and Hector Gomez. Dynamic cluster field modeling of collective chemotaxis, 2024.

[81] Quirine J. S. Braat, Cornelis Storm, and Liesbeth M. C. Janssen. Formation of motile cell clusters in heterogeneous model tumors: the role of cell-cell alignment, 2024.

[82] Hayri E Balcioglu, Rebecca Wijers, Marcel Smid, Dora Hammerl, Anita M Trapman-Jansen, Astrid Oostvogels, Mieke Timmermans, John WM Martens, and Reno Debets. Tme-analyzer: a new interactive and dynamic image analysis tool that identified immune cell distances as predictors for survival of triple negative breast cancer patients. *npj Imaging*, 2(1):21, 2024.

[83] Zahra Mokhtari, Elham Amjadi, Hamidreza Bolhasani, Zahra Faghih, AmirReza Dehghanian, and Marzieh Rezaei. Crc-icm: Colorectal cancer immune cell markers pattern dataset, 2023.

[84] Chris Roadknight, Uwe Aickelin, Alex Ladas, Daniele Soria, John Scholefield, and Lindy Durrant. Biomarker clustering of colorectal cancer data to complement clinical classification, 2013.

[85] Fayyaz Minhas, Michael S. Toss, Noor ul Wahab, Emad Rakha, and Nasir M. Rajpoot. L1-regularized neural ranking for risk stratification and its application to prediction of time to distant metastasis in luminal node negative chemotherapy naïve breast cancer patients, 2021.

[86] Jianhua Xing and Xiao-Jun Tian. Investigating epithelial-to-mesenchymal transition with integrated computational and experimental approaches, 2019.

[87] Keiko Itano. Mathematical modeling and analysis of the pathway network consisting of symmetrical complexes with n monomers, like the activation of mmp2, 2018.

[88] Chong Yu, Qiong Liu, Cong Chen, and Jin Wang. A physical mechanism of heterogeneity in stem cell, cancer and cancer stem cell, 2019.

[89] Xiao-Jun Tian, Hang Zhang, and Jianhua Xing. Coupled reversible and irreversible bistable switches underlying tgf-$\beta - inducedepithelialtomesenchymaltransition$, 2013.

[90] Tiago Gonçalves, Dagoberto Pulido-Arias, Julian Willett, Katharina V. Hoebel, Mason Cleveland, Syed Rakin Ahmed, Elizabeth Gerstner, Jayashree Kalpathy-Cramer, Jaime S. Cardoso, Christopher P. Bridge, and Albert E. Kim. Deep learning-based prediction of breast cancer tumor and immune phenotypes from histopathology, 2024.

[91] Li Zeng, Zhaolong Yu, and Hongyu Zhao. A pathway-based kernel boosting method for sample classification using genomic data, 2018.

[92] Teddy Lazebnik and Svetlana Bunimovich-Mendrazitsky. Predicting lung cancer's metastats' locations using bioclinical model, 2023.

[93] Edwin Wang, Naif Zaman, Shauna Mcgee, Jean-Sébastien Milanese, Ali Masoudi-Nejad, and Maureen O'Connor. Predictive genomics: A cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data, 2014.

[94] Radwa Adel and Ercan Engin Kuruoglu. Graph frequency features of cancer gene co-expression networks, 2024.

[95] Xia Jiang, Yijun Zhou, Alan Wells, and Adam Brufsky. Coalitions of ai-based methods predict 15-year risks of breast cancer metastasis using real-world clinical data with auc up to 0.9, 2024.

[96] Ethan M. Alt, Yixiang Qu, Emily Damone, Jing ou Liu, Chenguang Wang, and Joseph G. Ibrahim. Jointly modeling time-to-event and longitudinal data with individual-specific change points: a case study in modeling tumor burden, 2024.

[97] Siteng Chen, Jinxi Xiang, Xiyue Wang, Jun Zhang, Sen Yang, Junzhou Huang, Wei Yang, Junhua Zheng, and Xiao Han. Deep learning-based approach to reveal tumor mutational burden status from whole slide images across multiple cancer types, 2023.

[98] Marine Jeanmougin, Mickael Guedj, and Christophe Ambroise. Defining a robust biological prior from pathway analysis to drive network inference, 2011.

[99] Milena Pavlović, Ghadi S. Al Hajj, Chakravarthi Kanduri, Johan Pensar, Mollie Wood, Ludvig M. Sollid, Victor Greiff, and Geir Kjetil Sandve. Improving generalization of machine learning-identified biomarkers with causal modeling: an investigation into immune receptor diagnostics, 2023.

[100] Manan Shah, Christopher Rubadue, David Suster, and Dayong Wang. Deep learning assessment of tumor proliferation in breast cancer histological images, 2016.

[101] Dimakatso Alice Senthebane, Arielle Rowe, Nicholas Ekow Thomford, Hendrina Shipanga, Daniella Munro, Mohammad AM Al Mazeedi, Hashim AM Almazyadi, Karlien Kallmeyer, Collet Dandara, Michael S Pepper, et al. The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer. *International journal of molecular sciences*, 18(7):1586, 2017.

[102] Rebecca M. Crossley, Samuel Johnson, Erika Tsingos, Zoe Bell, Massimiliano Berardi, Margherita Botticelli, Quirine J. S. Braat, John Metzcar, Marco Ruscone, Yuan Yin, and Robyn Shuttleworth. Modeling the extracellular matrix in cell migration and morphogenesis: A guide for the curious biologist, 2024.

[103] Yitong Zheng, Dong Wang, Garrett Beeghly, Claudia Fischbach, Mark D. Shattuck, and Corey S. O'Hern. Computational modeling of the physical features that influence breast cancer invasion into adipose tissue, 2024.

[104] Julien Varennes and Andrew Mugler. Sense and sensitivity: physical limits to multicellular sensing, migration and drug response, 2016.

[105] Ushasi Roy, Tyler Collins, Mohit K. Jolly, and Parag Katira. Biophysical and biochemical mechanisms underlying collective cell migration in cancer metastasis, 2022.

[106] Chong Yu, Qiong Liu, Cong Chen, and Jin Wang. Quantification of the underlying mechanisms and relationship among cancer, metastasis and differentiation/development, 2018.

[107] David H. Margarit, Gustavo Paccosi, Marcela V. Reale, and Lilia M. Romanelli. Mapping cancer stem cell markers distribution:a hypergraph analysis across organs, 2024.

[108] Kazuma Inoue, Ryosuke Kojima, Mayumi Kamada, and Yasushi Okuno. An end-to-end framework for gene expression classification by integrating a background knowledge graph: application to cancer prognosis prediction, 2023.

[109] Manasa Gadde, Caleb Phillips, Neda Ghousifam, Anna G. Sorace, Enoch Wong, Savitri Krishnamurthy, Anum Syed, Omar Rahal, Thomas E. Yankeelov, Wendy A. Woodward, and Marissa Nichole Rylander. In vitro vascularized tumor platform for modeling tumor-vasculature interactions of inflammatory breast cancer, 2020.

[110] Tijana T. Ivancevic, Murk J. Bottema, and Lakhmi C. Jain. A mathematical model of chaotic attractor in tumor growth and decay, 2008.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.